ストックスクリーナーアプリを入手
3.61
2.96%
-0.11
Opus Genetics Inc (IRD) 最新ニュース
Opus Genetics (NASDAQ:IRD) Rating Increased to Hold at Zacks Research - MarketBeat
Opus Genetics Q3 EPS Lifted by Brookline Capital Markets - MarketBeat
Brokers Set Expectations for Opus Genetics FY2030 Earnings - MarketBeat
Opus Genetics FY2026 EPS Estimate Boosted by HC Wainwright - MarketBeat
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How FDA Alignment Is Shaping Opus Genetics' OPGx-LCA5 Development Strategy - clinicalleader.com
Opus Genetics completes phase 3 enrollment for OPGx-LCA5 gene therapy - glance.eyesoneyecare.com
Opus Genetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Opus Genetics Inc (IRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Opus Genetics (IRD) Gets a Buy from RBC Capital - The Globe and Mail
Piper Sandler Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Is Opus Genetics Inc (IRD) Significantly Overvalued After Q2 Ear - GuruFocus
OPUS GENETICSMAY OFFER AND SELL UP TO $300 MLN OF SECURITIESSEC FILING - Moomoo
Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen - MarketBeat
IRD Maintained by RBC Capital -- Price Target Lowered to $9.00 - GuruFocus
A. G. P. Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $9 to $10 - Moomoo
Opus GeneticsMay Offer And Sell Up To $300 Million Of SecuritiesSEC Filing - TradingView
RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating - marketscreener.com
Opus Genetics (NASDAQ: IRD) sets $300M shelf and $125M ATM stock plan - Stock Titan
Opus Genetics earnings beat by $0.02, revenue fell short of estimates - Investing.com Canada
Opus Genetics (NASDAQ:IRD) Releases Earnings Results - MarketBeat
Opus Genetics, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.14) — 10-Q Summary - TradingView
Opus Genetics (Nasdaq: IRD) hit by $73.6M loss, rising warrant costs - Stock Titan
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Opus Genetics Q2 revenue falls and misses estimates - TradingView
IRD: Gene therapy pipeline advances with strong cash position and key clinical milestones ahead - TradingView
Opus Genetics Reports Q2 2026 Results and Advances Multiple IRD Gene Therapy Programs with OPGx-BEST1 Data Expected in September - Quiver Quantitative
Opus Genetics reports Q2 2026 results: $0.8M revenue, $8.1M net loss, $88.8M cash - TradingView
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update - GlobeNewswire
Opus Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Opus Genetics Completes Phase 3 Enrollment for AAV Gene Therapy OPGx-LCA5 - BioPharm International
Opus Genetics (IRD) to Release Quarterly Earnings on Wednesday - MarketBeat
BTIG Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Opus Genetics completes enrollment in LCA5 gene therapy trial - Investing.com
Opus Genetics completes enrollment in LCA5 gene therapy trial By Investing.com - Investing.com South Africa
Opus Genetics Completes Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 For LCA5-Associated Inherited Retinal Disease - marketscreener.com
Opus Genetics completes patient enrollment in P... - pluang.com
Opus Genetics, Inc. $IRD Shares Sold by Perceptive Advisors LLC - MarketBeat
Opus Genetics, Inc. Revenue Breakdown – NASDAQ:IRD - TradingView
Opus Genetics Inc (IRD) Institutional Confidence - tradingkey.com
TD Cowen Initiates Opus Genetics at Buy - marketscreener.com
Opus Genetics, Inc. Revenue Breakdown – FWB:R3X1 - TradingView
Opus Genetics Inc (IRD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Opus Genetics CFO Robert Gagnon sells $22,941 in company stock - Investing.com
Form 4 Opus Genetics Inc For: 27 July By Investing.com - Investing.com India
Opus Genetics COO Joseph Schachle sells $13,653 in common stock By Investing.com - Investing.com Canada
Opus Genetics CEO George Magrath sells $27,925 in common stock By Investing.com - Investing.com Canada
Opus Genetics COO Joseph Schachle sells $13,653 in common stock - Investing.com
Opus Genetics CEO George Magrath sells $27,925 in common stock - Investing.com
Opus Genetics President Benjamin Yerxa Executes Automatic Sale of 7,429 Shares to Cover RSU Tax Withholding - Kalkine Media
Opus Genetics, Inc. (IRD) CFO auto-sells shares to cover RSU taxes - Stock Titan
Opus Genetics, Inc. (IRD) COO’s 4,644 shares sold to cover RSU tax withholding - Stock Titan
Opus Genetics (IRD) CEO sells shares to cover RSU-related tax obligations - Stock Titan
IRD|Opus Genetics Inc|Price:3.365|Chg%:+0.285 - TradingKey
Opus Genetics Inc (IRD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Opus Genetics Inc (IRD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IRD|Opus Genetics Inc|Price:3.080|Chg%:+0.160 - TradingKey
Opus Genetics Inc (IRD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Opus Genetics Inc (IRD) Cash Flow - TradingKey
Opus Genetics Inc (IRD) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
WDC: Western Digital Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Opus Genetics, Inc. (IRD) insider files to sell 7,783 shares under Rule 144 - Stock Titan
Opus Genetics, Inc. (IRD) insider files Form 144 to sell 9,475 shares - Stock Titan
Form 144 Opus Genetics For: 23 July By Investing.com - Investing.com South Africa
Opus Genetics (IRD) insider Joseph Schachle plans 15,625-share sale under Form 144 - Stock Titan
Inspire Pharmaceuticals (IRD) insider files to sell 25,000 shares under Rule 144 - Stock Titan
Top 3 Health Care Stocks That May Rocket Higher In JulyLegend Biotech (NASDAQ:LEGN), Anbio Biotechnolo - Benzinga
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):